Drug Trial Radar · NCT06266091
Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody
Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
115
Actual
Start
Nov 24, 2021
Primary completion
Feb 14, 2024
Study completion Aug 1, 2024
Sponsor
- Lead sponsor
- Wuhan YZY Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase II, Randomized, Open-label, Controlled, Multicenter Study to Evaluate the Efficacy and Safety of M701 in treating Patients with Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer combined with Systemic Therapy.
Conditions
- Malignant Ascites
Interventions
M701Drug
Intra-peritoneal infusion of M701 combined with system therapy
paracentesisDrug
paracentesis combined with system therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Puncture-free survival, PuFSTime frame: From the time of 4th dosing (Day 18) to the next puncture/drainage or death (up to 6 months)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Medical Center of Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.